NovaBridge Biosciences (NBP) EBITDA (2019 - 2025)
NovaBridge Biosciences (NBP) reported EBITDA of -$72.9 million for Q4 2025, down 92.69% year-over-year from -$997.8 million in Q4 2024, and down 764.12% on a QoQ basis from $11.0 million in Q3 2025.
NovaBridge Biosciences (NBP) has 5 years of EBITDA data on file, last reported at -$72.9 million in Q4 2025.
- Quarterly EBITDA fell 92.69% year-over-year to -$72.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$63.2 million (down 3432.53% YoY) and the FY2025 annual result came in at -$94.3 million, down 229.42% from the prior year.
- EBITDA declined to -$72.9 million in Q4 2025 per NBP's latest filing, from $11.0 million in the prior quarter.
- Across five years, EBITDA topped out at $25.1 million in Q2 2024 and bottomed at -$72.9 million in Q4 2025.
- The 3-year median for EBITDA is -$3.1 million (2025), against an average of -$11.2 million.
- Peak annual rise in EBITDA reached 1823.23% in 2025, while the deepest fall reached 120.58% in 2025.
- Tracing NBP's EBITDA over 3 years: stood at -$39.5 million in 2023, then climbed by 4.13% to -$37.8 million in 2024, then slumped by 92.69% to -$72.9 million in 2025.
- Per Business Quant, the three latest NBP EBITDA figures stand at -$72.9 million (Q4 2025), $11.0 million (Q3 2025), and $1.9 million (Q2 2025).
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -72.90 Mn |
| Sep 30, 2025 | 10.98 Mn |
| Jun 30, 2025 | 1.85 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | -37.83 Mn |
| Sep 30, 2024 | -637,000.00 |
| Jun 30, 2024 | 25.07 Mn |
| Mar 31, 2024 | 15.29 Mn |
| Dec 31, 2023 | -39.46 Mn |
| Sep 30, 2023 | -10.63 Mn |
| Jun 30, 2023 | -12.05 Mn |
| Dec 31, 2020 | -12.97 Mn |
| Sep 30, 2020 | 88.52 Bn |
| Dec 31, 2019 | -47.37 Mn |
| Sep 30, 2019 | -43.72 Mn |